Who are propofol, rocuronium and fentanyl's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propofol-rocuronium-and-fentanyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

propofol, rocuronium and fentanyl — Competitive Intelligence Brief

propofol, rocuronium and fentanyl (propofol, rocuronium and fentanyl) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anesthetic combination (intravenous anesthetic, neuromuscular blocking agent, opioid analgesic). Area: Anesthesiology.

marketed Anesthetic combination (intravenous anesthetic, neuromuscular blocking agent, opioid analgesic) GABA-A receptor (propofol); nicotinic acetylcholine receptor at neuromuscular junction (rocuronium); mu-opioid receptor (fentanyl) Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

propofol, rocuronium and fentanyl (propofol, rocuronium and fentanyl) — Al-Azhar University. This is a combination of three anesthetic and neuromuscular agents: propofol (GABA agonist for sedation), rocuronium (neuromuscular blocker), and fentanyl (opioid analgesic) used together for anesthesia induction and maintenance.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
propofol, rocuronium and fentanyl TARGET	propofol, rocuronium and fentanyl	Al-Azhar University	marketed	Anesthetic combination (intravenous anesthetic, neuromuscular blocking agent, opioid analgesic)	GABA-A receptor (propofol); nicotinic acetylcholine receptor at neuromuscular junction (rocuronium); mu-opioid receptor (fentanyl)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anesthetic combination (intravenous anesthetic, neuromuscular blocking agent, opioid analgesic) class)

Al-Azhar University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). propofol, rocuronium and fentanyl — Competitive Intelligence Brief. https://druglandscape.com/ci/propofol-rocuronium-and-fentanyl. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab